CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
|Podcasts|April 22, 2017
Podcast: This Week in Managed Care - Ending ACA Abuse, and Other News
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Advertisement
Every week, The American Journal of Managed Care® recaps the
In the last week, CMS issued a new rule to end abuse on the Affordable Care Act insurance exchanges; a study found that type 2 diabetes may possibly be reversed; and CareMore unveiled a new care model to deliver primary care from the dentist's chair.
Listen below or through one of these podcast services:
iTunes:
TuneIn:
Stitcher:
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
5